Aegis Capital Boosts PT on Catalyst Pharma (CPRX) to $7 Following Positive Firdapse Phase 3 Data
Tweet Send to a Friend
Aegis Capital lifts its price target on Catalyst Pharmaceutical Partners (Nasdaq: CPRX) from $6 to $7 and affirms its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
